A study published in the Annals of Allergy, Asthma & Immunology examined the impact of dupilumab (Dupixent) on the risk of psychiatric and sleep disorders in adults with atopic dermatitis (AD). Researchers conducted a retrospective cohort analysis using data from the TriNetX Global Collaborative Network, comparing patients newly prescribed dupilumab to those receiving conventional systemic treatments like corticosteroids, methotrexate, cyclosporine, or azathioprine.
After matching 6,114 patients in each cohort based on factors such as age, sex, race, and comorbidities, the study found that over a three-year follow-up period, the dupilumab group had significantly lower risks of developing:
Anxiety disorders
Depressive disorders
Adjustment disorders
Sleep disorders
The risk reduction for attention deficit hyperactivity disorder (ADHD) was not statistically significant.These protective effects were consistent across various subgroups, including different ages, sexes, races, and the presence of atopic comorbidities. Notably, Black or African American patients experienced a more pronounced reduction in risk for these disorders when treated with dupilumab.
The findings suggest that dupilumab may offer mental health benefits for individuals with AD, particularly among Black or African American populations. However, the authors recommend further research to fully understand the mechanisms behind these associations and to confirm the results.
Patients with atopic dermatitis prescribed Dupixent had a lower risk of psychiatric and sleep disorders, this was more evident in the African American population.

